// App-Quantinova.ai

EXTH-14 : INHIBITION OF THE ANGIOTENSIN II TYPE 2 RECEPTOR AT2R IS A NOVEL THERAPEUTIC STRATEGY FOR GLIOBLASTOMA

Researchers

Presenter

  • Richard Perryman

Principal Investigators

  • Hamidreza Shaye

  • Androniki Kostagianni

  • Antonis Tsiailanis

  • Tom Thorne

  • Maria Chatziathanasiadou

  • Gregory Sivolapenko

  • Mohamed Ahmed El Mubarak

  • Gye Won Han

  • Barbara Zarzycka

  • Vsevolod Katritch

  • Guillaume Lebon

  • Cristiana Lo Nigro

  • Laura Lattanzio

  • Sophie Morse

  • James Choi

  • Kevin O’Neill

  • Zoe Kanaki

  • Apostolos Klinakis

  • Tim Crook

  • Vadim Cherezov

  • Andreas Tzakos

  • Nelofer Syed

Medical Centers

  • Ospedale S. Croce e Carle, Cuneo, Italy

  • University of Patras,Patras,Greece

  • Biomedical Research Foundation of the Academy of Athens, Athens, Greece

  • UNIVERSITY OF IOANNINA, Ioannina, Greece

  • Genomics England, London, United Kingdom

  • University of Surrey, Guildford, USA

  • University of Montpellier, Montpellier, France

  • Imperial College London, London, United Kingdom

  • University of Southern California, Los Angeles, CA

Locations

  • Italy

  • United States

  • Greece

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Brain cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Angiotensin II

  • Temozolomide

  • Arrestin

  • EMA401

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved